A Naturalistic Controlled Trial of Individual Placement and Control in Bodø

NCT ID: NCT04179877

Last Updated: 2019-11-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

77000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to test the effectiveness of Individual Placement and Support (IPS) on

1. employment,
2. welfare dependency, and
3. public-sector health care utilization.

This is a naturalistic controlled trial, where one municipality (Bodø in Norway) with about 50000 inhabitants get access to IPS services in public sector mental health services during the period 2013-2016. The target group for the intervention is patients with severe mental illness (SMI) in the age group 18-40 at time of treatment. Patients already receiving lifelong disability benefits will be excluded.

The control group will be an average of 10 municipalities in Norway without IPS services.

Data for outcomes will be based on public registries available for research.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators aim test the hypotheses that Individual Placement and Support (IPS) is effective in

1. increasing employment,
2. reducing welfare dependency, and
3. reducing public-sector health care utilization.

This is a naturalistic controlled trial, where one municipality (Bodø in Norway) with about 50000 inhabitants get access to IPS services in public sector mental health services during the period 2013-2016. The follow-up period will last until 2022. The target group for the intervention is patients with severe mental illness (SMI) in the age group 18-40 at time of treatment, with an ambition of 200 received IPS services. The investigators aim to study the effectiveness on the societal (not individual) level, assuming spill-over effects within Bodø municipality as a result of system changes in the treatment municipality (Bodø). Patients already receiving lifelong disability benefits will be excluded. The control group will be 10 similar municipalities in Norway without IPS services and will be chosen on the basis of similarities in economy, demography and geography and collected from publicly available information. Approximately 77000 subjects will be enrolled in this study; 7000 subjects from Bodø municipality and 70000 from the other 10 municipalities (the control group).

Data for outcomes will be based on public registries available for research. Outcome operationalizations are:

1. Employment will be based on registry data from tax records with information both on employment (yes/no and period) and taxable income (NOK).
2. Welfare dependency will be based on registry data including rehabilitation benefits, disability benefits, sickness absence, unemployment benefits, and social benefits. These will be analysed separate and combined, and the main hypothesis will be based on the latter.
3. Health care utilization will be based on data from the Norwegian Patient Register. Data for in-patient and out-patients treatments for mental illness and other (separate analyses) will be used. These will be analysed separate and combined, and the main hypothesis will be based on the first.

The data will be analyzed in two rounds; first in 2019, and a follow-up analysis in 2022. A difference-in-difference approach will be used to measure the effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Mental Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Naturalistic controlled trial with one municipality (Bodø) as treatment group and 10 similar municipalities without IPS services as controls.
Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

The control municipalities are unaware of this project, and are thus masked to the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Individual placement and support

Group of patients receiving IPS to increase workforce participation.

Group Type EXPERIMENTAL

IPS

Intervention Type BEHAVIORAL

Occupational rehabilitation and support Integrated with clinical treatment

Control

Group of patients receiving treatment as usual.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IPS

Occupational rehabilitation and support Integrated with clinical treatment

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Severe mental illness
* Work assessment allowance

Exclusion Criteria

* Disability benefit
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nordlandssykehuset HF

OTHER

Sponsor Role collaborator

University of Tromso

OTHER

Sponsor Role collaborator

London School of Economics and Political Science

OTHER

Sponsor Role collaborator

University of Melbourne

OTHER

Sponsor Role collaborator

St George's Healthcare NHS Trust

OTHER

Sponsor Role collaborator

The University of New South Wales

OTHER

Sponsor Role collaborator

Norwegian Institute of Public Health

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arnstein Mykletun, Prof PsyD

Role: PRINCIPAL_INVESTIGATOR

Norwegian IPH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nordland Hospital Trust

Bodø, Nordland, Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IPSBODO

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.